ImmunoPrecise Antibodies: Strategic Partnerships and Proprietary Platforms Drive Speculative Buy Rating

ImmunoPrecise Antibodies (IPA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Wasserman from Benchmark Co. maintained a Buy rating on the stock and has a $3.00 price target.

Robert Wasserman has given his Buy rating due to a combination of factors that highlight ImmunoPrecise Antibodies’ potential for future growth. The company reported stable financial results for the third quarter of 2025, with revenues matching the previous year despite a significant impairment charge affecting net losses. Notably, the company’s proprietary platforms, LENSai and B-Cell Select, have driven increased product sales and demand, which are expected to continue boosting revenues.
Additionally, ImmunoPrecise Antibodies has entered into a promising $8-$10 million co-development partnership with a large biotech firm and has made strategic agreements with tech companies for AI-driven drug development. The company’s financial position has strengthened, with a significant increase in cash reserves and no long-term debt, further supported by insider share purchases. These developments, coupled with anticipated revenue growth from new contracts and services, underpin Wasserman’s optimistic outlook and the reiterated Speculative Buy rating with a $3 price target.

In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.